Clinical trials · Massachusetts
Smoldering Multiple Myeloma clinical trials in Massachusetts
We’re tracking 13 recruiting smoldering multiple myeloma studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT07393282RecruitingPhase 3
Comparing two treatments for high-risk smoldering multiple myeloma
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
Boston, MassachusettsAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05469893RecruitingPhase 2
Targeted treatment for high-risk smoldering myeloma
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT06138275RecruitingPhase 2
Elranatamab for relapsed multiple myeloma after Abecma
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Boston, MassachusettsAges 18 years+ - NCT06365060Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
Boston, MassachusettsAges 40 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Boston, MassachusettsAges 18 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Worcester, MassachusettsAges 18 years+ - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Brighton, MassachusettsAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Boston, MassachusettsAges 18 years+ - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
Boston, MassachusettsAges 18 years+ - NCT06215118RecruitingPhase 1
Combination therapy for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
Worcester, MassachusettsAges 18 years+ - NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Boston, MassachusettsAges 18 years+
Smoldering Multiple Myeloma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting smoldering multiple myeloma studies listed above.
- Dana-Farber Cancer Institute · 8 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Massachusetts General Hospital · 2 studies
- Tufts Medical Center · 2 studies
- Brigham and Women's Hospital
- Dana-Farber Brigham Cancer Center at South Shore Health
- Dana-Farber Cancer Institute - Merrimack Valley
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
What taking part in a smoldering multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Smoldering Multiple Myeloma trials in other states
Common questions
- Are there smoldering multiple myeloma clinical trials in Massachusetts?
- Yes. We're currently tracking 13 recruiting smoldering multiple myeloma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a smoldering multiple myeloma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a smoldering multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New smoldering multiple myeloma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.